Profil
Jeffrey Greve is the founder of Delinia, Inc. (founded in 2015) and Kyverna Therapeutics, Inc. (founded in 2018).
At Delinia, he held the title of Chief Scientific Officer.
At Kyverna Therapeutics, he held the title of Chief Scientific Officer from 2018 to 2022.
Dr. Greve's former job was as Vice President-Research at aTyr Pharma, Inc. Dr. Greve earned a doctorate degree from the University of Washington and an undergraduate degree from The Johns Hopkins University.
Anciens postes connus de Jeffrey Greve
| Sociétés | Poste | Fin |
|---|---|---|
| KYVERNA THERAPEUTICS, INC. | Fondateur | 23/08/2022 |
Delinia, Inc.
Delinia, Inc. BiotechnologyHealth Technology Develops novel therapeutics for the treatment of autoimmune diseases | Fondateur | - |
| ATYR PHARMA, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Jeffrey Greve
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
aTyr Pharma, Inc.
aTyr Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a bio therapeutics company that discovers and develops medicines based on novel biological pathways | Health Technology |
University of Washington
University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Johns Hopkins University
The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Delinia, Inc.
Delinia, Inc. BiotechnologyHealth Technology Develops novel therapeutics for the treatment of autoimmune diseases | Health Technology |
Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. BiotechnologyHealth Technology Operates as a cell therapy company which develops treatments and potential cures for serious autoimmune diseases | Health Technology |
















